Corcept Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	108.74	120.5	127.67	135.55	66.33	77.62
Short-Term Investments	229.45	251.66	255.67	232.67	365.34	145.92
Cash & Short-Term Investments	338.18	372.15	383.33	368.22	431.67	223.54
Cash Growth	4.78%	-2.92%	4.10%	-14.70%	93.11%	-49.28%
Accounts Receivable	39.07	59.79	53.98	41.12	31.06	27.63
Other Receivables	-	-	-	14	14	-
Total Trade Receivables	39.07	59.79	53.98	55.12	45.06	27.63
Inventory	12.89	12.87	12.41	7.73	6.1	4.99
Other Current Assets	35.89	40.66	21.88	27.56	16.42	10.32
Total Current Assets	426.03	485.46	471.6	458.64	499.25	266.46
Net Property, Plant & Equipment	10.37	6.47	8.01	0.32	1.78	1.52
Long-Term Investments	177.26	160.27	219.83	57.18	4.95	112.28
Other Long-Term Assets	201.22	184.44	141.11	105.39	77.45	43.5
Total Assets	814.88	836.65	840.55	621.52	583.43	423.76
Accounts Payable	33.31	40.44	15.38	17.4	11.98	6.91
Accrued Expenses	114.25	124.56	124.57	86.96	59.37	40.11
Current Portion of Leases	1.63	1.08	0.83	0.15	1.14	0.53
Total Current Liabilities	149.19	166.09	140.77	104.51	72.49	47.54
Long-Term Leases	8.01	5.02	6.11	-	-	-
Other Long-Term Liabilities	19.7	17.74	14.08	10.31	9.1	0.41
Total Long-Term Liabilities	27.71	22.76	20.19	10.31	9.1	0.41
Total Liabilities	176.89	188.85	160.96	114.81	81.59	47.95
Common Stock	0.14	0.14	0.14	0.13	0.13	0.13
Treasury Stock	-976.69	-966.59	-696.17	-635.08	-456.15	-410.41
Additional Paid-in Capital	1,002	968.6	832.11	738.52	662.34	591.35
Accumulated Other Comprehensive Income	0.92	2.26	-0.22	0.61	-0.87	-0.23
Retained Earnings	611.63	643.39	543.74	402.53	296.39	194.97
Shareholders' Equity	637.99	647.81	679.59	506.71	501.84	375.81
Total Liabilities & Equity	814.88	836.65	840.55	621.52	583.43	423.76
Total Debt	9.64	6.11	6.94	0.15	1.14	0.53
Net Cash (Debt)	328.55	366.05	376.4	368.07	430.53	223.01
Net Cash Growth	-10.24%	-2.75%	2.26%	-14.51%	93.05%	-49.10%
Net Cash Per Share	2.83	3.05	3.32	3.29	3.71	1.77
Book Value	637.99	647.81	679.59	506.71	501.84	375.81
Book Value Per Share	5.50	5.40	5.99	4.53	4.33	2.98
Tangible Book Value	637.99	647.81	679.59	506.71	501.84	375.81
Tangible Book Value Per Share	5.50	5.40	5.99	4.53	4.33	2.98

SEC Filings: 10-K · 10-Q